When analyzing the different IBS subgroups as classified using the Rome IV diagnostic criteria, the researchers observed that patients with IBS subtypes (n=149) other than the subtype causing diarrhea demonstrated the largest
Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome - read this article along with other careers information, tips and advice on BioSpace
Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome . | February 10, 2022